Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Severe chronic obstructive pulmonary disease has been an inhaler-based-therapy category for decades, with chronic macrolide and oral corticosteroid for selected exacerbation-prone patients. Dupilumab carries COPD approval in the eosinophilic phenotype, mepolizumab and benralizumab have reported COPD pivotal data, ensifentrine (PDE3/PDE4 inhibitor inhaled) provides a new class entry, and additional biologic programs are in late-stage trials. The category is acquiring a real biologic prescribing tier for the first time.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.